secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001193125-26-092528
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd Q4 PEMGARDA revenue $17.2M (+31% QoQ); VYD2311 DECLARATION trial fully enrolled, top-line mid-2026
--------------------------------------------------------------------------------

- Q4 2025 PEMGARDA net revenue $17.2M (up 25% YoY, 31% QoQ); FY2025 revenue $53.4M vs $25.4M in 2024.
- Cash and equivalents $226.7M at Dec 31, 2025; raised over $200M in 2H 2025.
- FY2025 net loss $52.5M ($0.30/share) vs $169.9M ($1.43/share) in 2024; R&D expenses fell to $38.3M.
- DECLARATION Phase 3 trial for VYD2311 fully enrolled; IDMC allows pregnant/breastfeeding women; top-line data expected mid-2026.
- Appointed Michael Mina, M.D., Ph.D., as CMO; Fast Track designation for VYD2311 granted Dec 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312526092528/0001193125-26-092528-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312526092528/d118119d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-092528

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer